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1. Main Messages
•	 Screening	for	pre-diabetes	followed	by	diet	&	exercise	or	metformin	is	cost-effective	and	should	be	
considered	for	incorporation	into	current	practice.
•	 	Workforce	capacity	of	dietitians	and	exercise	physiologists	to	deliver	lifestyle	change	interventions	will	
need	to	be	increased	to	appropriately	support	the	intervention.	
2. Background
Diabetes	is	a	leading	cause	of	morbidity	and	mortality	worldwide.		In	Australia,	9.6%	of	fatal	and	non-fatal	
health	loss	measured	in	disability	adjusted	life	years	(DALYs)	and	12.6%	of	all	deaths	are	attributed	to	type	2	
diabetes.	Pre-diabetes	is	when	an	individual	has	impaired	fasting	glucose	or	impaired	glucose	tolerance	but	is	
not	yet	considered	to	have	diabetes.	The	aim	of	this	study	is	to	evaluate	the	cost-effectiveness	of	a	screening	
program	for	pre-diabetes	followed	by	treatment	with	pharmaceutical	interventions	(acarbose,	metformin,	
orlistat	or	rosiglitazone)	and	lifestyle	interventions	(diet,	exercise	or	diet	and	exercise	combined)	in	the	2003	
Australian	population.	
3. interventions
We	reviewed	the	diabetes	literature	to	identify	a	range	of	interventions	that	prevent	or	delay	the	onset	of	
diabetes	in	people	with	pre-diabetes.	In	order	to	identify	people	who	have	pre-diabetes,	a	screening	program	
through	general	practitioners	was	modelled.	The	screening	program	targets	people	visiting	a	general	
practitioner	over	the	age	of	45	with	at	least	one	risk	factor	for	diabetes	(such	as	age,	family	history,	high	BMI,	
previous	gestational	diabetes	etc)	who	are	invited	to	undergo	a	fasting	blood	glucose	test	and	an	oral	glucose	
tolerance	test.	Those	identified	with	pre-diabetes	are	then	eligible	for	a	preventive	intervention.	
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From	the	review	process,	we	selected	three	pharmaceutical	interventions	and	three	lifestyle	intervention	programs	for	cost-effectiveness	
analysis:
a)	 Pharmacotherapy: Acarbose:	A	drug	treatment	that	prevents	the	release	of	glucose	from	carbohydrates.	
Treatment	is	100mg	three	times	per	day.
b)	 Pharmacotherapy: Metformin:	A	drug	treatment	that	lowers	the	level	of	glucose	in	the	blood.	
Treatment	is	850mg	two	times	per	day.
c)	 Pharmacotherapy: Orlistat:	A	drug	treatment	that	prevents	the	body	from	absorbing	fat	from	foods.	
Treatment	is	120mg	three	times	per	day.
d)	 Lifestyle: Diet:	Involves	group	counselling	by	a	dietician	weekly	for	one	month,	monthly	for	the	next	three	months	and	
three	monthly	thereafter.
e)	 Lifestyle: Exercise:	Involves	group	counselling	by	an	exercise	physiologist	weekly	for	one	month,	monthly	for	the	next	three	months	
and	three	monthly	thereafter.
f )	 Lifestyle: Diet & Exercise:	Involves	group	counselling	by	both	a	dietician	and	an	exercise	physiologist	weekly	for	one	month,	
monthly	for	the	next	three	months	and	three	monthly	thereafter.
4. cHoice of coMparator
The	comparator	to	the	interventions	is	current	practice.	There	is	currently	no	systematic	screening	in	place	for	pre-diabetes	in	Australia	
and	no	pharmaceutical	treatments	are	approved	for	pre-diabetes	on	the	PBS.		In	determining	the	optimum	mix	of	interventions,	we	
assume	none	of	the	interventions	of	interest	were	currently	in	place.			
5. intervention cost-effectiveness
The	interventions	predominately	fall	in	the	north-east	(‘health	gain	at	a	cost’)	quadrant	of	the	cost-effectiveness	plane	(Figure).	A	
combined	diet	and	exercise	intervention	has	a	greater	probability	of	being	cost-effective	than	either	diet	or	exercise	alone.	Metformin	
has	similar	cost-effectiveness	credentials	to	the	diet	and	exercise	intervention	(Table).
	Figure:	Cost-effectiveness	of	six	diabetes	prevention	interventions	aimed	at	people	aged	45+	illustrated	on	a	cost-effectiveness	plane	
with	$50,000	per	DALY	threshold	line	
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e) Lifestyle: Exercise: Involves group counselling by an exercise physiologist weekly 
for ne month, monthly for the next three month  and three monthly thereafter. 
f) Lifestyle: Diet & Exercise: Involves group counselling by both a dietician and an 
exercise physiologist weekly for one month, monthly for the next three months and 
three monthly thereafter. 
4. Choice of comparator 
The comparator to the interventions is current practice. There is currently no systematic 
screening in place for pre-diabetes in Australia and no pharmaceutical treatments are 
approved for pre-diabetes on the PBS.  In determining the optimum mix of interventions, we 
assume none of the interventions of interest were currently in place.    
5. Intervention cost-effectiveness 
The int rv tions predomin t ly fall in the n rth- ast (‘health gain at a cost’) qua rant of th  
cost-effectiveness plane (Figure). A combined diet and exercise intervention has a greater 
probability of being cost-effective than either diet or exercise alone. Metformin has similar 
cost-effectiveness credentials to the diet and exercise intervention (Table). 
 
Figure: Cost-effectiveness of six diabetes prevention interventions aimed at people aged 45+ 
illustrated on a cost-effectiveness plane with $50,000 per DALY threshold line  
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Table:	Cost-effectiveness	ratios	and	probability	of	being	cost-effective	for	the	six	diabetes	prevention	interventions	when	compared	to	
current	practice	
A	combined	diet	&	exercise	intervention	or	metformin	are	the	most	cost-effective	interventions.	An	incremental	analysis	of	adding	the	
two	interventions	together	did	not	indicate	cost-effectiveness,	with	an	ICER	of	$67,000	per	DALY	to	add	diet	&	exercise	to	metformin.
6. conclusions
Screening	for	pre-diabetes	followed	by	diet	&	exercise	or	metformin	is	cost-effective	and	should	be	considered	for	incorporation	into	
current	practice.	Workforce	capacity	of	dietitians	and	exercise	physiologists	to	deliver	lifestyle	change	interventions	will	need	to	be	
increased	to	appropriately	support	the	intervention.	
7. ace-prevention
To	aid	priority	setting	in	prevention,	the	Assessing	Cost-Effectiveness	in	Prevention	Project	(ACE-Prevention)	applies	standardised	
evaluation	methods	to	assess	the	cost-effectiveness	of	100	to	150	preventive	interventions,	taking	a	health	sector	perspective.	This	
information	is	intended	to	help	decision	makers	move	resources	from	less	efficient	current	practices	to	more	efficient	preventive	action	
resulting	in	greater	health	gain	for	the	same	outlay.
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Table: Cost-effectiveness ratios and probability of being cost-effective for the six diabetes 
prevention interventions when compared to current practice  
Intervention Average CER ($/DALY Averted) Uncertainty interval 
Diet & exercise $23,000 $19,000-$35,000 
Metformin $22,000 $17,000-$36,000 
Exercise $30,000 $23,000-$89,000 
Acarbose $37,000 $25,000-$134,000 
Diet $38,000 $23,000-$148,000 
Orlistat $100,000 $94,000-$130,000 
A combined diet & exercise intervention or metformin are the most cost-effective 
interventions. An incremental analysis of adding the two interventions together did not 
indicate ost-effectiveness, with an ICER of $67,000 per DALY to add diet & exercise to 
metformin. 
6. Conclusions 
Screening for pre-diabetes followed by diet & exercise or metformin is cost-effective and 
should be considered for in orporation into curr t practice. Workforc  capacity of dietitians 
and exercise physiologists to deliver lifestyle change interventions will need to be increased 
to appropriately support the intervention.  
7. ACE-Prevention 
To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project 
(ACE-Prevention) applies standardised evaluation methods to assess the cost-effectiveness 
of 100 to 150 preventive interventions, taking a health sector perspective. This information is 
intended to help decision makers move resources from less efficient current practices to 
more efficient preventive action resulting in greater health gain for the same outlay. 
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